Arkolith/Insider Trading/VYNE/Form 4

Harsch Mutya

CHIEF LEGAL OFFICER AND GCVYNE Therapeutics Inc. (VYNE) · full profile →Form 4 · filed Jan 23, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 21, 2025Grant(A)230K—$0230K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-001924) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML